HomeAbout Karis BioOur History
2020
AUGUST 14, 2020
Found Karis Bio Inc.
Dr. Young-sup Yoon established company, Karis Bio Inc., using innovative cell-based therapy techniques for treatment of cardiovascular diseases.
AUGUST 15, 2020
Locate at Yonsei University Severance Hospital
Locate at Avison Biomedical Research Center, Rm 525, Yonsei-Ro 50-1, Seodaemun-Ku, Seoul, 03722, Republic of Korea
SEPTEMBER, 2020
Awarded U-Tech Valley Business by Korea Technology Finance Corporation
DECEMBER, 2020
Funded by Angel Investors
[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]
2021
MAY, 2021
Received investments from major 5 Investors
Korea Development Bank, Premier Partners, Aju IB Investment, Seoul IP, Devsisters Ventures
Series A 103억원 투자유치
May 15, 2021
Karis Bio R&D center certified by Korea Industrial Technology Association
July 14, 2021
Venture Business certified by Korea Venture Business Association
August 15, 2021
Selected for the 2021 Material Component Technology Development Project by the Ministry of Trade, Industry and Energy (MOTIE), Korea
Karis Bio Inc. is the only organization selected in the Bio sector, as the lead agency of the 2021 Material Component Technology Project, supported by the Ministry of Trade, Industry and Energy (MOTIE) and managed by the Korea Institute for Advancement of Technology (KIAT). A total of KRW 2.6 billion is provided for research and development for three years.
September 16, 2021
Provided the world’s first proof for cardiac stem cell therapy in regenerative medicine
Nature Biomedical Engineering (IF: 26.671): Through a direct conversion method of fibroblasts, “directly reprogrammed cardiac-like tissue“ including major cardiac cells and extracellular matrix was generated and confirmed its therapeutic effect and heart regeneration in a mouse model.
October 20, 2021
“Good-Bio Award“ in the “Cell Therapy for Cardiovascular Disease” category
Karis Bio Inc. has won the “Good-Bio Award” in the “Cell Therapy for Cardiovascular Disease” category at the “7th Korea Good Company Awards 2021,“ hosted by Money Today.
November 1, 2021
Approved by the committee on the Advanced Regenerative Medicine Research under the Ministry of Health and Welfare
December 9, 2021
Dr. Young-sup, Yoon, the CEO of Karis Bio Inc., on the KBS 20th anniversary special program, called “Mysteries of the Human Body”
Dr. Young-sup, Yoon, CEO of Karis Bio Inc. and a cardiologist, scientist and professor in the Division of Cardiology, Emory University (USA), was interviewed on the TV show, Mysteries of the Human Body, to explain the Karis Bio’s technology that can help treat cardiovascular disease, the world’s leading cause of death.
[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]
2022
Jan 2, 2022
Established of Karis Bio USA in Atlanta, GA
May 13, 2022
Selected for a research project of Global Vaccine Leading Technology Center, supported by the Ministry of Health and Welfare, Korea
Karis Bio Inc. participates in the vaccine-based technology development project organized by the Global Vaccine Leading Technology Center under the Ministry of Health and Welfare, Korea.
May 20, 2022
Opened a Gasan branch office of Karis Bio Inc.
Karis Bio Inc. has established a branch office in the Seoul Digital Industrial Complex in Gasan-dong (Korea) and held an opening ceremony.
Sep 05, 2022
“Good-Bio Award“ for two consecutive years
‘Karis Bio Inc. was awarded the “Good-Bio Award” in the “Cell Therapy for Cardiovascular Disease” category for the second consecutive year at the “8th Korea Good Company Awards 2022.
Nov 02, 2022
Established a cGMP (cleanroom) facility
Karis Bio Inc. opened a cGMP facility in the Seoul Digital Industrial Complex in Korea, to manufacture the first domestic clinical trial of induced pluripotent stem cell (iPSC)-derived cell therapy products.
Dec 27, 2022
Selected for a Tech Investor Program for Scale-up (Scale-up TIPS)
Karis Bio Inc. is selected for the “2022 Investment-oriented R&D Scale-up TIPS“ project by the Ministry of SMEs and Startups.
[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]
2023
Jan 18, 2023
Series B financing
Series B fundraising (Korea Development Bank, Premier Partners, Aju IB Investment, Devsisters Ventures)
Apl 07, 2023
Received a grant for a Regenerative Medicine Technology Development Project from the Korean Fund for Regenerative Medicine (KFRM)
Karis Bio Inc. is collaborating with Yonsei University Office of Research Affairs and University-Industry Foundation (UIF) to jointly develop regenerative medicine technologies for a total of 33 months, from April 2023 to the end of 2025.
May 09, 2023
KarisBio, Inc. CEO Yoon Young-sup’s research team discovers new genes for cardiovascular regeneration
Mr. Yoon Young-sup’s, the CEO of Karis Bio, Inc. an innovative cardiovascular therapeutics development company, has led a research team that has identified the mechanism behind the decreased regenerative capacity of myocardial cells. They have also discovered a method to enhance the proliferative ability of myocardial cells, ultimately leading to cardiac regeneration.
[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]
© 2021 KARIS BIO INC. ALL RIGHTS RESERVED